Bristol-Myers Squibb Company (BMY)
PCE/Core PCE Inflation In Line With Estimates in June
PCE/Core PCE Inflation In Line With Estimates in June.
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.
Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.75 per share a year ago.
Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings.
Global sales of Eliquis, a drug used to reduce the risk of stroke and blood clots, increase 7% in the second quarter from a year earlier.
Bristol Myers second-quarter results beat expectations, helped by new drugs
Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thinner Eliquis and a portfolio of drugs it expects to help it deliver long-term growth.
Growth Portfolio Will Likely Drive Bristol Myers Squibb's Q2
Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q2 2024 results on Friday, July 26. We expect BMY stock to trade higher, with its revenue and earnings likely exceeding the street estimates.
2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You?
Dividend payers tend to outperform businesses that aren't committed to distributing a portion of earnings to shareholders. Bristol Myers Squibb offers a yield above 5% at recent prices.
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
